Engineered Osteoclasts for the Treatment and Prevention of Heterotopic Ossification

Abstract

Heterotopic ossification (HO) is the abnormal formation of bone in soft tissues and is a frequent complication in patients who have suffered traumatic brain and spinal cord injuries. Currently there are few effective treatments for this condition. This research seeks to develop engineered osteoclasts as a local cell therapy for the prevention and/or regression of HO. The goals of this research are to develop proof-of-principle data in excised human HO specimens and in an animal model using existing murine engineered osteoclasts and to develop an off-the-shelf human induced pluripotent stem (iPS) cell source for clinical translation of this technology. To date we have performed studies to optimize various hydrogel formations as cell delivery vehicles. We will use these hydrogels to retain engineered osteoclasts at sites of HO in vivo. We have also created and validated a lentiviral vector containing an inducible human RANK fusion gene that will be used to develop our human iPS cell source.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2014
Accession Number
ADA613014

Entities

People

  • Bruce Sangeorzan
  • Cameron Rementer
  • Cecilia Giachelli
  • Dewayne Threet
  • Steven Brain
  • Susan Lund

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Cell Line
  • Cells
  • Culture Techniques
  • Gels
  • Heterotopic Ossification
  • Hydrogels
  • Implantation
  • Macrophages
  • Osteogenesis
  • Soft Tissues
  • Spinal Cord
  • Spinal Injuries
  • Stem Cells
  • Stromal Cells
  • Surgical Implantation
  • Tissues
  • Translations

Fields of Study

  • Medicine

Readers

  • Aerial Delivery - Logistics and Supply Chain Management.
  • Oncology (Cancer Research).
  • Trauma Surgery or Emergency Medicine.